The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus

Table 1

Clinical and laboratory characteristics in patients with SLE and healthy controls.

Clinical characteristics	SLE, 𝑁 (%)^a	Healthy controls	𝑃 value^b
Age	34.63±12.92	35.5±9.75	0.100
Sex (female : male)	95 : 13	34 : 8	0.196
Disease duration (months)	68.16±72.00	NA
ANA (%)	98/108 (90.74)	NA
Anti-dsDNA Ab (%)	51/108 (47.22)	NA
ACL (%)	26/108 (24.07)	NA
AnuA (%)	55/108 (50.93)	NA
Sm (%)	26/108 (24.07)	NA
SSA (%)	45/108 (41.67)	NA
24 h proteinuria (%)	69/108 (63.89)	NA
Lupus nephritis (%)	46/108 (42.59)	NA
Decreased C3 (%)	85/108 (78.70)	NA
Decreased C4 (%)	68/108 (62.96)	NA
SLEDAI	9.44±8.32	NA

SLEDAI: systemic lupus erythematosus disease activity index; ANA: antinuclear antibody; Anti-dsDNA Ab: anti-double strand DNA Antibody; ACL: anticardiolipin antibody; AnuA: antinucleosome antibody; Sm: anti-Sm antibody; SSA: anti-SSA antibody; C3: Complement component 3; C4: Complement component 4. ^aValues are represented as either mean or number: 𝑁 (%). NA: not applicable. Numerical data were presented as mean ± SD and analyzed using the student’s 𝑡-test or Pearson’s Chi-squared test. ^b𝑃<0.05 as significant.